A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Nature Medicine

Volumn 23, Issue 4, 2017, Pages 461-471

  Bruno, Peter M ^a   Liu, Yunpeng ^a   Park, Ga Young ^a   Murai, Junko ^b   Koch, Catherine E ^a   Eisen, Timothy J ^a,c   Pritchard, Justin R ^a   Pommier, Yves ^b   Lippard, Stephen J ^a   Hemann, Michael T ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN; PHOSPHOTRANSFERASE; ANTINEOPLASTIC AGENT; PHENANTHRIDINE DERIVATIVE; PHENANTHRIPLATIN; PLATINUM COMPLEX; PLATINUM DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOGENESIS; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE RESPONSE; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIBOSOME; RIBOSOME BIOGENESIS STRESS; STRESS; ANIMAL; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; HUMAN; NEOPLASM; ORGANELLE BIOGENESIS; PHYSIOLOGICAL STRESS; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; HUMANS; MICE; NEOPLASMS; ORGANELLE BIOGENESIS; ORGANOPLATINUM COMPOUNDS; PHENANTHRIDINES; PLATINUM COMPOUNDS; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMES; RNA, SMALL INTERFERING; STRESS, PHYSIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85014524566     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4291     Document Type: Article

References (67)

1. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584 (2007).
2. Chu, E. & v DeVita Jr, V.T. Physician's Cancer Chemotherapy Drug Manual (Jones & Bartlett Learning Oncology, Sudbury, 2008).
3. Rixe, O. et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. 52, 1855-1865 (1996).
4. Machover, D. et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7, 95-98 (1996).
5. Jiang, H., Pritchard, J.R., Williams, R.T., Lauffenburger, D.A. & Hemann, M.T. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat. Chem. Biol. 7, 92-100 (2011).
6. Pritchard, J.R. et al. Defining principles of combination drug mechanisms of action. Proc. Natl. Acad. Sci. USA 110, E170-E179 (2013).
7. Pritchard, J.R., Bruno, P.M., Hemann, M.T. & Lauffenburger, D.A. Predicting cancer drug mechanisms of action using molecular network signatures. Mol. Biosyst. 9, 1604-1619 (2013).
8. Suntharalingam, K. et al. Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. J. Am. Chem. Soc. 135, 14060-14063 (2013).
9. Suntharalingam, K. et al. A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. J. Am. Chem. Soc. 136, 14413-14416 (2014).
10. Suntharalingam, K. et al. Necroptosis-inducing rhenium(V) oxo complexes. J. Am. Chem. Soc. 137, 2967-2974 (2015).
11. Awuah, S.G., Zheng, Y.-R., Bruno, P.M., Hemann, M.T. & Lippard, S.J.A. Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy. J. Am. Chem. Soc. 137, 14854-14857 (2015).
12. Boodram, J.N. et al. Breast cancer stem cell potent copper(II)-non-steroidal anti-inflammatory drug complexes. Angew. Chem. Int. Ed.Engl. 55, 2845-2850 (2016).
13. Cressey, P.B. et al. The potent inhibitory effect of a naproxen-appended cobalt(III)-cyclam complex on cancer stem cells. ChemBioChem 17, 1713-1718 (2016).
14. Zheng, Y.-R. et al. Mechanistic studies of the anticancer activity of an octahedral hexanuclear Pt(II) cage. Inorganica Chim. Acta 452, 125-129 (2016).
15. Barnes, J.C. et al. Using an RNAi signature assay to guide the design of three-drug-conjugated nanoparticles with validated mechanisms, in vivo efficacy, and low toxicity. J. Am. Chem. Soc. 138, 12494-12501 (2016).
16. Zamble, D.B., Mu, D., Reardon, J.T., Sancar, A. & Lippard, S.J. Repair of cisplatin - DNA adducts by the mammalian excision nuclease. Biochemistry 35, 10004-10013 (1996).
17. Fojo, T. et al. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Crit. Rev. Oncol. Hematol. 53, 25-34 (2005).
18. Alvarez, M. et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J. Clin. Invest. 95, 2205-2214 (1995).
19. Willett, P., Barnard, J.M. & Downs, G.M. Chemical similarity searching. J. Chem. Inf. Comput. Sci. 38, 983-996 (1998).
20. Williams, R.T., Roussel, M.F. & Sherr, C.J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 103, 6688-6693 (2006).
21. Maede, Y. et al. Differential and common DNA repair pathways for topoisomerase I-and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol. Cancer Ther. 13, 214-220 (2014).
22. Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).
23. Rogakou, E.P., Nieves-Neira, W., Boon, C., Pommier, Y. & Bonner, W.M. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 275, 9390-9395 (2000).
24. Bonner, W.M. et al. GammaH2AX and cancer. Nat. Rev. Cancer 8, 957-967 (2008).
25. Olive, P.L. & Banáth, J.P. The comet assay: a method to measure DNA damage in individual cells. Nat. Protoc. 1, 23-29 (2006).
26. Golomb, L., Volarevic, S. & Oren, M. p53 and ribosome biogenesis stress: the essentials. FEBS Lett. 588, 2571-2579 (2014).
27. Boulon, S., Westman, B.J., Hutten, S., Boisvert, F.M. & Lamond, A.I. The nucleolus under stress. Mol. Cell 40, 216-227 (2010).
28. Liu, J., Xu, Y., Stoleru, D. & Salic, A. Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc. Natl. Acad. Sci. USA 109, 413-418 (2012).
29. Bliss, C.I. The calculation of microbial assays. Bacteriol. Rev. 20, 243-258 (1956).
30. Reinhold, W.C. et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72, 3499-3511 (2012).
31. Huang, W., Sherman, B.T. & Lempicki, R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
32. Huang, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
33. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
34. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
35. Muzny, D.M. et al.; Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
36. Faller, W.J. et al. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 517, 497-500 (2015).
37. Koboldt, D.C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
38. Raymond, E., Chaney, S.G., Taamma, A. & Cvitkovic, E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 9, 1053-1071 (1998).
39. Raymond, E., Lawrence, R., Izbicka, E., Faivre, S. & Von Hoff, D.D. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res. 4, 1021-1029 (1998).
40. Shelley, M.D., Burgon, K. & Mason, M.D. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. Cancer Treat. Rev. 28, 237-253 (2002).
41. Goldberg, R.M. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
42. Raez, L.E. et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer 53, 347-353 (2006).
43. Atmaca, A. et al. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br. J. Cancer 108, 265-270 (2013).
44. Scagliotti, G.V. et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin. Cancer Res. 11, 690-696 (2005).
45. Yardley, D.A. et al. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer. Cancer Invest. 28, 865-871 (2010).
46. Njiaju, U.O. et al. Capecitabine and oxaliplatin in combination as first-or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial. Cancer Chemother. Pharmacol. 71, 613-618 (2013).
47. Guerrero, A. et al. Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer. Anticancer Drugs 22, 283-289 (2011).
48. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
49. Meijers-Heijboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2(∗)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31, 55-59 (2002).
50. Samimi, G. et al. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother. Pharmacol. 55, 1-11 (2005).
51. Kim, M.K. et al. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol. Cancer Ther. 11, 1500-1509 (2012).
52. Bertucci, F. et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23, 1377-1391 (2004).
53. Arango, D. et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 129, 874-884 (2005).
54. Barrier, A. et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J. Clin. Oncol. 24, 4685-4691 (2006).
55. Yamasaki, M. et al. The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int. J. Oncol. 30, 129-138 (2007).
56. Bandrés, E. et al. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol. Rep. 17, 1089-1094 (2007).
57. Fritzmann, J. et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 137, 165-175 (2009).
58. Zoncu, R., Efeyan, A. & Sabatini, D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35 (2011).
59. Voss, M.H. et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin. Cancer Res. 20, 1955-1964 (2014).
60. Spranger, S., Bao, R. & Gajewski, T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231-235 (2015).
61. Woynarowski, J.M. et al. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol. 58, 920-927 (2000).
62. Burger, K. et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol. Chem. 285, 12416-12425 (2010).
63. Dickins, R.A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289-1295 (2005).
64. Zuber, J. et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat. Biotechnol. 29, 79-83 (2011).
65. Zhao, B., Pritchard, J.R., Lauffenburger, D.A. & Hemann, M.T. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 4, 166-174 (2014).
66. Park, G.Y., Wilson, J.J., Song, Y. & Lippard, S.J. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc. Natl. Acad. Sci. USA 109, 11987-11992 (2012).
67. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).